HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mundorf, T.K. Articles by Earl, M. Search for Related Content PubMed Articles by Mundorf, T.K. Articles by Earl, M.

A Multicenter, Investigator–Masked, Randomized Comparison of the IOP–Lowering Efficacy of Bimatoprost 0.03% versus Travoprost 0.004% in African Americans with Glaucoma or Ocular Hypertension

¹ Charlotte, NC
² Ophthalmology, University of Arizona School of Medicine, Tucson, AZ
³ IMEDS, Riverside, CA

Commercial Relationships: T.K. Mundorf, Allergan C; R. Noecker, Allergan C; M. Earl, None.

Grant Identification: none

Abstract

Purpose: To compare the IOP–lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in African Americans with glaucoma or ocular hypertension.

Methods: Randomized, investigator–masked, multicenter, parallel–design clinical trial. After completing a washout of all ocular hypotensive agents, patients were randomized to bimatoprost QD (n=25) or travoprost QD (n=24) for 3 months. Study visits were at baseline and months 1, 2, and 3. The primary outcome measure was IOP.

Results: There were no significant differences in baseline mean IOP (P=.146). Bimatoprost provided lower mean IOP than travoprost at the month 2 and 3 study visits. After 2 months of study medication, the mean IOP in the bimatoprost group was 17.7 mm Hg and 19.2 mm Hg in the travoprost group (P=.043). After 3 months, the mean IOP was 16.8 mm Hg in the bimatoprost group and 18.5 mm Hg in the travoprost group (P=.068). Mean IOP reductions ranged from 6.2 to 8.0 mm Hg (25.8% to 32.5%) with bimatoprost and from 5.9 to 6.9 mm Hg (23.2% to 27.6%) with travoprost.

Conclusions: The findings of the present study suggest that bimatoprost is more effective than travoprost for IOP–lowering in African Americans with glaucoma or ocular hypertension.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials

© 2004, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. For permission to reproduce any part of this abstract, contact the ARVO Office at arvo{at}arvo.org.